young biotech company created a new therapeutic class research innovative logo
Wollen Sie auch einen Job wie diesen gewinnen?
Dieser Kunde bekam 7 Logo-Designs von 4 Designern. Dabei wurde dieses Logo-Design Design von alexis alemán als Gewinner ausgewählt.
Kostenlos anmelden Design Jobs finden- Gebündeltes Projekt 2
Logo-Design Kurzbeschreibung
our logo should be recognizable quickly evoke a therapeutic target, the colors are a mix of blue and sienna (dark orange) the title of the company has pharma but the word must be included in a letter (see example below) H4 ORPHAN PHARMA is a small pharmaceutical company Whose objective is to Develop first in class drugs for the treatment of orphan diseases.H4 ORPHAN PHARMA choose to Develop Idiopathic Pulmonary Fibrosis (IPF). The physiopathology of COPD, severe asthma and IPF are similar. H4 ORPHAN PHARMA chooses to Develop pharmaceutical program on orphan diseases (pulmonary fibrosis and cystic fibrosis) with unmet need. IPF is a disabling and fatal disease Ultimately That affects Approximately 200,000 patients in the USA and Europe, with Approximately 45,000 new cases per year. The median survival time from diagnosis is entre 2 and 5 years, with a 5-years survival rate of Approximately 20%. I want new color (blue or similar with an other color as sienna but i am AGREE with an other color if according with the blue
Zielmarkt/( -märkte)
GlobalData Expects IPF dirty therapy across USA, France, Germany, Italy, Spain and UK to rise from $ 49m in 2012 to over $ 1.1 trillion by 2017. The EU HAS so far Dominated the GEM market, purpose the US is set to reclaim market share in the future. In 2022, it is planned by various analysts That Esbriet (Marketed since 2012) shoulds Realize a turnover of $ 2 trillion and Slightly less for OVEF (new product on the market). In 2022, the market is expected to be about $ 4 trillion. H4 ORPHAN PHARMA is Positioned as a development company for new pharmaceutical concepts. Its objective is to make the licensing out for ict discoveries in Phase I or Phase II in (clinical proof of concept). H4 ORPHAN PHARMA will Develop CP554 up to Phase I or Phase II And Then make a licensing out with a big pharma company
Kontaktinformationen für Visitenkarte
Gaëtan TERRASSE ,MD
CEO
Mob + 33 664 900 654
H4 orphan pharma
20 rue jean Mazen
21 000 DIJON
FRANCE
mail: gaetanterrasse@h4orphan.com
www.h4orphan.com
Logo Text
H4 ORPHAN PHARMA
Sehen und fühlen
Jeder Schieber zeichnet eine der Charakteristiken der Marke des Kunden aus sowie den Stil, den euer Logo widerspiegeln sollte.
Elegant
Fett
Spielerisch
Ernst
Traditionel
Modern
Sympatisch
Professionell
Feminin
Männlich
Bunt
Konservativ
Wirtschaftlich
Gehobenes
Dateien
Zahlungen
Gesamt
€275
Projekt-Deadline
03 Apr 2016 13:07:44 UTCProjekt Upgrades
Gebündelte(s) Projekt(e)
- übergebe €24 Briefpapier-Design an den Sieger
- übergebe €14 Visitenkarten-Design an den Sieger